NICM
IOVA icon

Neo Ivy Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Neo Ivy Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-453,138
Closed -$3.35M – 355
2024
Q4 		$3.35M Buy
+453,138
New +$4.2M 0.68% 61
2024
Q3 		– Sell
-212,648
Closed -$1.71M – 331
2024
Q2 		$1.71M Buy
+212,648
New +$2.28M 0.33% 127
2022
Q2 		– Sell
-292
Closed -$4K – 503
2022
Q1 		$4K Sell
292
-2,609
-90% -$40.3K ﹤0.01% 454
2021
Q4 		$55K Buy
+2,901
New +$63.9K 0.08% 268
2021
Q2 		– Sell
-3,215
Closed -$102K – 523
2021
Q1 		$102K Buy
3,215
+148
+5% +$6.13K 0.11% 240
2020
Q4 		$142K Buy
3,067
+1,549
+102% +$61.5K 0.16% 204
2020
Q3 		$49K Buy
+1,518
New +$46.5K 0.05% 363
2020
Q2 		– Sell
-693
Closed -$21K – 520
2020
Q1 		$21K Buy
+693
New +$18.4K 0.03% 376

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Neo Ivy Capital Management's IOVA Position: Q1 2025 in Review

Neo Ivy Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 453,138 shares — an estimated $3.35M sold.

Neo Ivy Capital Management first reported a position in IOVA in Q1 2020 and held it in 8 quarters. The position peaked at $3.35M in Q4 2024. 302 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Neo Ivy Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Neo Ivy Capital Management sold 453,138 Iovance Biotherapeutics shares in Q1 2025, an estimated $3.35M.
  • Neo Ivy Capital Management first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 8 quarters.
  • Neo Ivy Capital Management's Iovance Biotherapeutics position peaked at $3.35M in Q4 2024.
  • 302 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Neo Ivy Capital Management's 13F filing for Q1 2025, filed 6 May 2025.